Additionally, these data suggest that FR-β expression may be a useful indicator of a tumor's metastatic potential and that the receptor might be exploited for folate-mediated drug targeting to certain cancers and their associated anti-inflammatory macrophages. This evidence concerns the gene FOLR2 and neoplasm.